Monday, 08 August, 2016

Insomnia Treatment Market Faces Steep Decline to 2016, but New Drugs Will Aid Recovery

Insomnia drug sales will fall rapidly from $2.1 billion in 2013 to $1.4 billion by 2016, before steadily recovering to $1.8 billion by 2023, driven by the launch of two products, Merck & Co.'s Belsomra and Eisai's E-2006, and an increase in the prevalent cases of insomnia.
 
The sharp initial decline, which will occur across seven major markets, namely the US, France, Germany, Italy, Spain, UK, and Japan, will be primarily due to the generic erosion of Sunovion/Dainippon Sumitomo's Lunesta…


Category: Aerospace & Defense
No Comment
Tags: sunovion dainippon sumitomo's lunesta (eszopiclone)